With the health of China's economy deteriorating, private equity investors have every reason to expect to see plenty of opportunities to deploy capital in 2019
Weimob, a Shanghai-based provider of marketing and cloud services to online merchants that is backed by Tencent Holdings and several private equity firms, has surged 14% on its first day of trading on the Hong Kong Stock Exchange.
The Carlyle Group has promoted Ling Yang, a managing director in the firm’s Shanghai office, to partner. Yang is one of 60 senior promotions announced by Carlyle worldwide, including six in the Asia buyout team.
Lightspeed China Partners took just three months to raise $560 million for its fourth US dollar fund, which includes a $200 million sidecar for follow-on investments
Chinese eye hospital chain operator Chaoju Ophthalmology has raised RMB400 million ($59 million) in a Series B round of funding backed by Orchid Asia Group and River Head Capital.
Ping An Insurance and CITIC Group have made a Series B investment of undisclosed size in Airdoc, a Chinese medical services company that uses artificial intelligence (AI).
Chinese logistics firm Yimidida has raised RMB1.8 billion ($266.1 million) in a Series D round of funding led by Boyu Capital.
CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
Beijing and Shanghai-based Medbanks, an information service provider specializing in cancer care, has raised RMB400 million ($59 million) in Series C funding led by CLP Fund.
Sequoia Capital China and HighLight Capital have led a RMB550 million ($80 million) pre-IPO funding round for BrightGene Bio-Medical Technology, a Chinese developer of innovative and generic drugs. An investment unit of GF Securities also participated.
TPG Capital and CICC Capital, the private equity arm of China International Capital Corporation (CICC), have agreed to establish a joint platform that will make investments in US dollars and renminbi.
Bain Capital’s recent investment and exit activity underlines the importance of cross-border competencies. The GP also won the awards for Deal of the Year - Large Cap and Exit of the Year - Large Cap
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
Chinese online healthcare services provider Zhiyun Health has raised $100 million in a Series C round of funding across two tranches.
Nreal, a China-based company that makes advanced virtual reality glasses that resemble normal sunglasses, has raised $15 million in Series A funding from investors including Shunwei Capital.
Chinese early-stage investor China Renaissance K2 Ventures (K2VC) has publicly attacked Next Capital - a spin-out from the venture capital firm - for allegedly stealing confidential information.
VC fundraising has been on a roll in Asia as managers raise larger sums to address fast-growing investment opportunities. GPs must consider what – and how much – makes them stand out from the crowd
360 Enterprise Security, a Chinese B2B internet security software provider that spun-out from Qihoo 360, has closed a Series B round of funding worth RMB900 million ($132 million), achieving a valuation of RMB20.6 billion.
China Everbright has reached a final close of $539 million on its cross-border investment fund, with the commitments coming from corporate investors, family offices, and fund-of-funds.
China-based healthcare care services provider Miaoshou Doctor has raised RMB500 million ($72.8 million) in an extended Series C round of funding led by Starquest Capital, with participation from Sequoia Capital China.
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
WeRide.ai, a Chinese autonomous driving technology specialist formerly known as Jingchi.ai, has raised several hundred millions of US dollars in an extended Series A round led by local artificial intelligence (AI) company SenseTime.
Shenzhen Capital Group has reached a first close of RMB1.8 billion ($263 million) on its debut M&A fund. The vehicle has an overall target of RMB3.6 billion.
New Alliance Capital has led a $45 million Series A round for China-based contract research and manufacturing services provider Thousand Oaks Biopharmaceuticals, with participation by Addor Capital and several other healthcare-focused investors.